# CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

> **NCT05896124** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cascade Pharmaceuticals, Inc** · enrollment: 75 (actual)

## Conditions studied

- Primary Biliary Cholangitis (PBC)

## Interventions

- **DRUG:** 2mg CS0159
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05896124
- **Lead sponsor:** Cascade Pharmaceuticals, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-07
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-03-15
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896124, "CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05896124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*